PMV Pharmaceuticals

Apitope is a biotechnology company dedicated to discovering and developing disease-modifying therapies for autoimmune and allergic diseases. Its research primarily targets conditions such as multiple sclerosis, Graves’ disease, Factor VIII intolerance, and uveitis. Utilizing a proprietary platform technology, Apitope develops antigen-specific therapeutic peptides aimed at addressing the underlying causes of these diseases. The company’s innovative approach seeks to enhance patients' quality of life by providing treatments that minimize the risk of secondary infections and complications. Apitope's first product candidate has been licensed to a major pharmaceutical partner, Merck Serono, while the company continues to advance its remaining portfolio of therapeutic candidates.

FF Pharma is a biopharmaceutical company focused on developing innovative therapies for chronic inflammatory diseases, specifically targeting conditions such as primary biliary cirrhosis and Crohn’s disease. The company is advancing an anti-CD40 monoclonal antibody therapy that acts as a negative allosteric modulator of the CD40 pathway. This therapy serves as a reversible switch for B cell activation, inhibiting aberrant immune responses associated with autoimmune diseases. By targeting the CD40 pathway, FF Pharma aims to provide effective treatment options for patients suffering from chronic inflammation and related disorders.